Search
Thursday 11 June 2015
  • :
  • :
Latest Update

Bears of the Day: Parsley Energy (NYSE:PE), Rentech, (NASDAQ:RTK), Charter Communications, (NASDAQ:CHTR), Halozyme Therapeutics, (NASDAQ:HALO)

On Wednesday, Parsley Energy Inc (NYSE:PE)’s shares declined -2.73% to $17.10.

Parsley Energy Inc (PE) declared financial and operating results for the quarter ended March 31, 2015. The Company has posted to its website a presentation that supplements the information in this release.

First Quarter 2015 Highlights

  • Parsley delivered record quarterly net production of 18.9 MBoe/d, an enhance of 4% over Q4 2014 and up 106% year-over-year.
  • Parsley is raising full-year 2015 production guidance from 18-19 MBoe/d to 20-21.5 MBoe/d.
  • Wolfcamp B well productivity—already among the best in the Midland Basin—improved for the fourth successive quarter.
    • The three Wolfcamp B wells Parsley accomplished in its Core area in Q1 2015 with 30 days of production had peak 30-day initial production (IP) rates per 1,000-foot lateral of 231 Boe/d on average, up 30% as compared to average peak 30-day IP rates for Wolfcamp B wells accomplished in its Core area in Q1 2014.
  • Parsley drilled its most productive Wolfcamp A well to date, registering a peak 30-day IP rate per 1,000-foot lateral of 188 Boe/d on the Mary 18A-18-2H.

Parsley Energy, Inc., an independent oil and natural gas company, engages in the acquisition, development, production, exploration, and sale of crude oil and natural gas properties in the Permian Basin located in West Texas and Southeastern New Mexico. As of December 31, 2014, its acreage position comprised of 133,274 net acres, counting 103,036 net acres in the Midland Basin and 30,238 net acres in the Delaware Basin; and estimated proved oil and natural gas reserves were 90.9 MMBoe.

Rentech, Inc. (NASDAQ:RTK)’s shares dropped -2.63% to $1.11.

Rentech, Inc. (RTK) declared financial and operating results for the three months ended March 31, 2015.

Three months ended March 31, 2015

Merged revenues for the first quarter of 2015 were $105.6 million, contrast to $82.3 million in the preceding year period. These revenues were comprised of:

  • $22.7 million from Fulghum, a decrease of $3.4 million from the preceding year period;
  • $12.1 million from NEWP;
  • $1.7 million from Wood Pellets: Industrial; and
  • $69.2 million from Rentech Nitrogen, an enhance of $12.9 million from the preceding year period.

Gross profit for the first quarter of 2015 was $24.3 million, contrast to $17.9 million in the preceding year period. Gross profit was comprised of:

  • $3.7 million from Fulghum, which was a decrease of $0.4 from the preceding year period;
  • $2.2 million from NEWP;

New England Wood Pellet

Revenues were $12.1 million, counting $1.2 million from the Allegheny mill, for the first quarter of 2015 on deliveries of 63,000 tons of wood pellets. Gross profit was $2.2 million and gross profit margin was 18%. Adjusted EBITDA was $2.3 million, and net income was $1.1 million.

Rentech, Inc., through its auxiliaries, provides wood fiber processing services, wood chips, and wood pellets. The company operates through five segments: East Dubuque; Pasadena; Fulghum Fibres; Wood Pellets: Industrial; and Wood Pellets: NEWP. It manufactures and sells natural-gas based nitrogen fertilizer products in North and South America.

At the end of Wednesday’s trade, Charter Communications, Inc. (NASDAQ:CHTR)‘s shares dipped -2.58% to $176.95.

Charter Communications, Inc. (CHTR) and Advance/Newhouse jointly declared that the companies remain committed to concluding their formerly declared transaction on the same economic and governance terms. The companies have extended their good faith negotiating period for an additional 30 days under the formerly declared agreement for Charter to acquire Bright House Networks (“Bright House”) for $10.4 billion. Bright House is the sixth largest cable operator in the United States, and serves about 2 million video customers in central Florida counting Orlando and Tampa Bay, in addition to Alabama, Indiana, Michigan, and California.

Charter Communications, Inc., through its auxiliaries, provides entertainment, information, and communications solutions to residential and commercial customers in the United States. The company offers cable video programming services, counting basic and digital video, premium channels, on-demand, pay-per-view, high definition television, and digital video recorder services, in addition to Charter TV App, which enables video customers to search and discover content on various devices, counting the iPhone, iPad, iPod Touch, and Android based tablets.

Halozyme Therapeutics, Inc. (NASDAQ:HALO), ended its Wednesday’s trading session with -2.38% loss, and closed at $16.85.

Halozyme Therapeutics, Inc. (HALO) stated financial results for the first quarter ended March 31, 2015. Financial highlights comprise revenues of $18.7 million and a net loss of $15.1 million, or $0.12 per share, contrast to revenues of $12.0 million and a net loss of $26.5 million, or $0.22 per share, for the first quarter of 2014.

First Quarter 2015 Financial Highlights

  • Revenues for the first quarter of 2015 were $18.7 million, contrast to $12.0 million for the first quarter of 2014. Revenues in the first quarter comprised of $6.8 million in royalty revenue from sales of products under partnership agreements, $6.1 million in product sales of bulk rHuPH20 for use in manufacturing partnership products for Roche, $3.8 million in Hylenex®recombinant(hyaluronidase human injection) product sales, and $2.0 million in partnership revenues. Royalty revenues represent October to December 2014 sales as a result of the one quarter lag in royalty reports.
  • Research and development expenses for the first quarter of 2015 were $16.7 million, contrast to $21.4 million for the first quarter of 2014. The decrease was primarily due to a planned decrease in expenses associated with the diabetes program.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.

 




Leave a Reply

Your email address will not be published. Required fields are marked *